Study of the safety, pharmacodynamics and efficancy of KRN23 in children from 1 to 4 years old with X-linked Hypophosphatemia (XLH). (sciencenews.org)
April 17, 2018 Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita ® (burosumab - twza) for the Treatment of Children and Adults with X — Linked Hypophosphatemia (XLH) (ultragenyx.com)
Many cats become hypokalemic and some develop hypophosphatemia severe enough to produce hemolysis. (academic.oup.com)